CoChat

Na+/H+ exchanger activity is increased in doxorubicin‐resistant human colon cancer cells and its modulation modifies the sensitivity of the cells to doxorubicin

Open access
Miraglia, Erica, Viarisio, Daniele, Riganti, Chiara, Costamagna, Costanzo, Ghigo, Dario, Bosia, Amalia · 2005 · International Journal of Cancer
Cited by 86

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

Multidrug resistant (MDR) tumor cells exhibit an altered pH gradient across different cell compartments, which favors a reduced intracellular accumulation of antineoplastic drugs and a decreased therapeutic effect. In our study, we have observed that the activity and expression of Na+/H+ exchanger (NHE), which is involved in the homeostasis of intracellular pH (pH i), are increased in doxorubicin‐resistant (HT29‐dx) human colon carcinoma cells in comparison with doxorubicin‐sensitive HT29 cells. The pH i was significantly higher in HT29‐dx cells, which accumulated less doxorubicin than HT29 cells. The NHE inhibitor 5‐(N‐ethyl‐N‐isopropyl)amiloride (EIPA) significantly reduced the pH i value and increased the intracellular accumulation of doxorubicin in both cell populations: in the presence of EIPA HT29‐dx cells accumulated as much drug as control HT29 cells. On the other hand, monensin, a Na+/H+ ionophore mimicking NHE activation, and phorbol 12‐myristate 13‐acetate (PMA), which stimulates NHE, significantly increased the pH i and decreased the drug accumulation in HT29 cells to values similar to those observed in control HT29‐dx cells. EIPA potentiated the cytotoxic effect of doxorubicin in HT29 cells, and made HT29‐dx cells as sensitive to the cytotoxic effect of the drug as control HT29 cells. Instead, PMA and monensin made HT29 cells as insensitive to doxorubicin as HT29‐dx cells. These results suggest that in MDR cells the higher cytosolic pH is likely to decrease drug accumulation, and that such resistance can be reverted by inhibiting the NHE activity. This result opens the possibility to revert MDR with the clinical use of NHE inhibitors. © 2005 Wiley‐Liss, Inc.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/ijc.20959

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

  • Multidrug resistance in cancer: role of ATP–dependent transporters

    Gottesman, M. M., Fojo, T., & Bates, S. E. (2002) · Nature Reviews Cancer · doi:10.1038/nrc706 · Cited by 5,536 · cited 4×

    “' 2005 Wiley-Liss, Inc. Key words: multidrug resistance; Naþ/Hþ exchanger; colon carcinoma; doxorubicin Multidrug resistance (MDR) includes the numerous strategies by which tumor cells can elude the cytotoxic effect of chemotherapeutic agents and develop cross-resistance to a broad spectrum of drugs.1 Decreased accumu…”
    BackgroundInfluential

Cited by

See all 86

Metadata

Authors
Miraglia, E., Viarisio, D., Riganti, C., Costamagna, C., Ghigo, D., & Bosia, A.
Venue
International Journal of Cancer
Publisher
Wiley
Published
2005-02-23
Volume
115
Issue
6
Pages
924-929
ISSN
  • 0020-7136 (ISSN-L)
  • 1097-0215
OpenAlex
W2030139214
Cited by
86
References
1
FWCI
0.85
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.